Stuart Sedlack has been appointed senior vice president of business development at Velocity Pharmaceutical Development (VPD). Mr. Sedlack will have primary responsibility for identifying business opportunities to help build the company's business, as well as partnering and monetizing compounds that have achieved clinical proof of concept. He reports to David Collier, MD, VPD's chief executive officer and managing director of CMEA Capital.
Mr. Sedlack has significant experience sourcing, negotiating and managing partnerships in the life science industry. Most recently, he was senior vice president, corporate development at Amarin Pharmaceuticals, and served on the executive management team. He was responsible for strategic and operational initiatives including building and managing a network of contract manufacturing relationships.
Mr. Sedlack also held positions in international banking, spent six years with Elan Corp. as a key member of its corporate investment and licensing group, and served as vice president of corporate development. After Elan, he served as global head of negotiations for Novartis' Infectious Disease business unit, where he negotiated a number of transactions to help establish Novartis’ presence in the field.
"I am delighted to welcome Stuart to the Velocity team," said Dr. Collier. "Stuart's deep experience in partnering, corporate strategy, finance and pharmaceutical development make him an ideal addition to Velocity. I greatly look forward to working with him."